Compare MTDR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | BLCO |
|---|---|---|
| Founded | 2003 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Ophthalmic Goods |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2012 | 2022 |
| Metric | MTDR | BLCO |
|---|---|---|
| Price | $41.24 | $17.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 14 |
| Target Price | ★ $61.71 | $17.31 |
| AVG Volume (30 Days) | ★ 1.4M | 352.7K |
| Earning Date | 02-17-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.24 | N/A |
| Revenue | $3,556,751,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $14.67 | $8.06 |
| Revenue Next Year | N/A | $5.79 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | ★ 14.75 | 6.23 |
| 52 Week Low | $35.19 | $10.45 |
| 52 Week High | $64.05 | $18.34 |
| Indicator | MTDR | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 58.18 |
| Support Level | $40.50 | $16.22 |
| Resistance Level | $44.20 | $17.26 |
| Average True Range (ATR) | 1.28 | 0.34 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 20.00 | 83.97 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.